| Literature DB >> 35999392 |
Minglu Yan1, Noriko Komatsu1, Ryunosuke Muro1, Nam Cong-Nhat Huynh1,2, Yoshihiko Tomofuji3, Yukinori Okada3,4,5, Hiroshi I Suzuki6,7, Hiroyuki Takaba1, Riko Kitazawa8, Sohei Kitazawa9, Warunee Pluemsakunthai1, Yuichi Mitsui10,11, Takashi Satoh10,11, Tadashi Okamura12, Takeshi Nitta1, Sin-Hyeog Im13,14,15, Chan Johng Kim13, George Kollias16,17, Sakae Tanaka18, Kazuo Okamoto19, Masayuki Tsukasaki1, Hiroshi Takayanagi20.
Abstract
Fibroblasts, the most abundant structural cells, exert homeostatic functions but also drive disease pathogenesis. Single-cell technologies have illuminated the shared characteristics of pathogenic fibroblasts in multiple diseases including autoimmune arthritis, cancer and inflammatory colitis. However, the molecular mechanisms underlying the disease-associated fibroblast phenotypes remain largely unclear. Here, we identify ETS1 as the key transcription factor governing the pathological tissue-remodeling programs in fibroblasts. In arthritis, ETS1 drives polarization toward tissue-destructive fibroblasts by orchestrating hitherto undescribed regulatory elements of the osteoclast differentiation factor receptor activator of nuclear factor-κB ligand (RANKL) as well as matrix metalloproteinases. Fibroblast-specific ETS1 deletion resulted in ameliorated bone and cartilage damage under arthritic conditions without affecting the inflammation level. Cross-tissue fibroblast single-cell data analyses and genetic loss-of-function experiments lent support to the notion that ETS1 defines the perturbation-specific fibroblasts shared among various disease settings. These findings provide a mechanistic basis for pathogenic fibroblast polarization and have important therapeutic implications.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35999392 DOI: 10.1038/s41590-022-01285-0
Source DB: PubMed Journal: Nat Immunol ISSN: 1529-2908 Impact factor: 31.250